Investor Presentation First Nine Months of 2023
113
Investor presentation
First nine months of 2023
International Operations at a glance
Novo NordiskⓇ
Million
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
DKK
billion
19%
MS
First nine months
of 2023
Sales
(mDKK)
Growth²
17%
Injectable GLP-13
23,812
46%
250
100%
600
Rybelsus®
5,303
178%
Total GLP-1
29,115
60%
200
80%
39.4%¹
GLP-1
Total insulin4
28,279
-1%
400
720
150
60%
Other Diabetes care5
1,531
-21%
Insulin
Diabetes care
58,925
21%
587
487
100
2.2%1
40%
Obesity care
6,019
52%
200
50
OAD
20%
Diabetes & Obesity
64,944
24%
9.1%1
care
0
0
0%
2021
2030
Population with diabetes
Diabetes growth rate
2045
Aug
2018
Aug
2023
Rare disease?
Total
7,446
-22%
72,390
17%
GLP-1 MS
-
-Insulin MS
OAD MS
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific; Source: International Diabetes
Federation: Diabetes Atlas 10th Edition 2021
1 CAGR calculated for 5-year period; Competitor insulin value market shares, as of
Aug 2023: Novo Nordisk 51%, Others 49%; Competitor GLP-1 value market shares,
as of Aug 2023: Novo Nordisk 69%, Other 31%; OAD: Oral anti-diabetic; MS: Market
share; Source: IQVIA MAT, Aug 2023 value figures; Market values are based on the
list prices
2 At Constant exchange rates; 3 Comprises Victoza®, Ozempic®;
4 Comprises TresibaⓇ, XultophyⓇ, Levemir®, RyzodegⓇ, Novo Mix®, FiaspⓇ and
NovoRapidⓇ; 5 Comprises Novo NormⓇ and needles; 6 Obesity care comprises
SaxendaⓇ and Wegovy®: 7 Comprises primarily NovoSeven®, Novo Eight®
NovoThirteen®, Refixia®, Esperoct®, Norditropin®, Vagifem® and ActivelleⓇView entire presentation